Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial with a Safety Extension

Summary

Randomized placebo-controlled study with an extension evaluating tesamorelin in adults living with HIV who had excess abdominal fat accumulation.

Limitations

The indication-specific population limits generalization to ordinary obesity. Effects on visceral fat diminish after discontinuation, and glucose-related and neoplasm-related precautions are important.

Linked peptides

• Tesamorelin